Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study.

Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, Atun R, Robotham JV, Deeny SR.

PLoS One. 2019 Sep 10;14(9):e0221944. doi: 10.1371/journal.pone.0221944. eCollection 2019.

2.

Mathematical modelling to study the horizontal transfer of antimicrobial resistance genes in bacteria: current state of the field and recommendations.

Leclerc QJ, Lindsay JA, Knight GM.

J R Soc Interface. 2019 Aug 30;16(157):20190260. doi: 10.1098/rsif.2019.0260. Epub 2019 Aug 14.

3.

Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling.

Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ.

Lancet Infect Dis. 2019 Aug;19(8):903-912. doi: 10.1016/S1473-3099(19)30307-X. Epub 2019 Jul 4.

4.

Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling.

Rhodes SJ, Knight GM, Kirschner DE, White RG, Evans TG.

J Theor Biol. 2019 Mar 21;465:51-55. doi: 10.1016/j.jtbi.2019.01.017. Epub 2019 Jan 10.

5.

Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.

Harris RC, Sumner T, Knight GM, Evans T, Cardenas V, Chen C, White RG.

Lancet Glob Health. 2019 Feb;7(2):e209-e218. doi: 10.1016/S2214-109X(18)30452-2. Epub 2019 Jan 7.

6.

Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.

Rhodes SJ, Guedj J, Fletcher HA, Lindenstrøm T, Scriba TJ, Evans TG, Knight GM, White RG.

NPJ Vaccines. 2018 Sep 17;3:36. doi: 10.1038/s41541-018-0075-3. eCollection 2018.

7.

A Case-Control Study to Identify Community Venues Associated with Genetically-clustered, Multidrug-resistant Tuberculosis Disease in Lima, Peru.

Bui DP, Oren E, Roe DJ, Brown HE, Harris RB, Knight GM, Gilman RH, Grandjean L.

Clin Infect Dis. 2019 Apr 24;68(9):1547-1555. doi: 10.1093/cid/ciy746.

PMID:
30239609
8.

Quantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling study.

Knight GM, Costelloe C, Deeny SR, Moore LSP, Hopkins S, Johnson AP, Robotham JV, Holmes AH.

BMC Med. 2018 Aug 23;16(1):137. doi: 10.1186/s12916-018-1121-8.

9.

Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.

Knight GM, Dyakova E, Mookerjee S, Davies F, Brannigan ET, Otter JA, Holmes AH.

BMC Med. 2018 Aug 16;16(1):141. doi: 10.1186/s12916-018-1117-4.

10.

The relative fitness of drug-resistant Mycobacterium tuberculosis: a modelling study of household transmission in Peru.

Knight GM, Zimic M, Funk S, Gilman RH, Friedland JS, Grandjean L.

J R Soc Interface. 2018 Jun;15(143). pii: 20180025. doi: 10.1098/rsif.2018.0025.

11.

Potential impact of influenza vaccine roll-out on antibiotic use in Africa.

Knight GM, Clarkson M, de Silva TI.

J Antimicrob Chemother. 2018 Aug 1;73(8):2197-2200. doi: 10.1093/jac/dky172.

12.

Estimating the burden of antimicrobial resistance: a systematic literature review.

Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, Knight GM, Robotham JV.

Antimicrob Resist Infect Control. 2018 Apr 25;7:58. doi: 10.1186/s13756-018-0336-y. eCollection 2018.

13.

Addressing the Unknowns of Antimicrobial Resistance: Quantifying and Mapping the Drivers of Burden.

Knight GM, Costelloe C, Murray KA, Robotham JV, Atun R, Holmes AH.

Clin Infect Dis. 2018 Feb 1;66(4):612-616. doi: 10.1093/cid/cix765.

14.

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods.

Rhodes SJ, Sarfas C, Knight GM, White A, Pathan AA, McShane H, Evans TG, Fletcher H, Sharpe S, White RG.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00525-16. doi: 10.1128/CVI.00525-16. Print 2017 Mar.

15.

A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e00498-16. doi: 10.1128/AAC.00498-16. Print 2017 Mar.

16.

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.

Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, Wells WA, Cobelens FG, Vassall A.

BMC Infect Dis. 2016 Dec 1;16(1):726.

17.

Methods for estimating the burden of antimicrobial resistance: a systematic literature review protocol.

Naylor NR, Silva S, Kulasabanathan K, Atun R, Zhu N, Knight GM, Robotham J.

Syst Rev. 2016 Nov 8;5(1):187.

18.

The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions.

Rhodes SJ, Zelmer A, Knight GM, Prabowo SA, Stockdale L, Evans TG, Lindenstrøm T, White RG, Fletcher H.

Vaccine. 2016 Dec 7;34(50):6285-6291. doi: 10.1016/j.vaccine.2016.10.060. Epub 2016 Nov 2.

19.

Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines.

Harris RC, Sumner T, Knight GM, White RG.

Hum Vaccin Immunother. 2016 Nov;12(11):2813-2832. Epub 2016 Jul 22. Review.

20.

Isolation demand from carbapenemase-producing Enterobacteriaceae screening strategies based on a West London hospital network.

Vella V, Moore LS, Robotham JV, Davies F, Birgand GJ, Otter JA, Brannigan E, Dyakova E, Knight GM, Mookerjee S, Holmes AH.

J Hosp Infect. 2016 Oct;94(2):118-24. doi: 10.1016/j.jhin.2016.04.011. Epub 2016 Apr 22.

21.

Ebola: the hidden toll of tuberculosis.

Knight GM, Houben RM, Lalli M, White RG.

Public Health Action. 2016 Mar 21;6(1):2. doi: 10.5588/pha.16.0019. No abstract available.

22.

The transmission of Mycobacterium tuberculosis in high burden settings.

Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, White RG, Cohen T, Cobelens FG, Wood R, Moore DA, Abubakar I.

Lancet Infect Dis. 2016 Feb;16(2):227-38. doi: 10.1016/S1473-3099(15)00499-5. Epub 2016 Jan 26. Review. Erratum in: Lancet Infect Dis. 2016 Mar;16(3):279.

PMID:
26867464
23.

Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status.

Rhodes SJ, Knight GM, Fielding K, Scriba TJ, Pathan AA, McShane H, Fletcher H, White RG.

Tuberculosis (Edinb). 2016 Jan;96:37-43. doi: 10.1016/j.tube.2015.10.002. Epub 2015 Nov 11.

24.

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.

Knight GM, Gomez GB, Dodd PJ, Dowdy D, Zwerling A, Wells WA, Cobelens F, Vassall A, White RG.

PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015.

25.

Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making.

Knight GM, Dharan NJ, Fox GJ, Stennis N, Zwerling A, Khurana R, Dowdy DW.

Int J Infect Dis. 2016 Jan;42:17-23. doi: 10.1016/j.ijid.2015.10.024. Epub 2015 Nov 3. Review.

26.

The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.

Knight GM, Colijn C, Shrestha S, Fofana M, Cobelens F, White RG, Dowdy DW, Cohen T.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S147-54. doi: 10.1093/cid/civ579.

27.

Within-host diversity of MRSA antimicrobial resistances.

Stanczak-Mrozek KI, Manne A, Knight GM, Gould K, Witney AA, Lindsay JA.

J Antimicrob Chemother. 2015 Aug;70(8):2191-8. doi: 10.1093/jac/dkv119. Epub 2015 May 8.

28.

Tuberculosis prevention in South Africa.

Knight GM, Dodd PJ, Grant AD, Fielding KL, Churchyard GJ, White RG.

PLoS One. 2015 Apr 7;10(4):e0122514. doi: 10.1371/journal.pone.0122514. eCollection 2015.

29.

The complex evolution of antibiotic resistance in Mycobacterium tuberculosis.

Fonseca JD, Knight GM, McHugh TD.

Int J Infect Dis. 2015 Mar;32:94-100. doi: 10.1016/j.ijid.2015.01.014. Review.

30.

Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.

Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW.

Open Forum Infect Dis. 2014 Aug 30;1(2):ofu073. doi: 10.1093/ofid/ofu073. eCollection 2014 Sep.

31.

Ebola: the power of behaviour change.

Funk S, Knight GM, Jansen VA.

Nature. 2014 Nov 27;515(7528):492. doi: 10.1038/515492b. No abstract available.

PMID:
25428491
32.

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15520-5. doi: 10.1073/pnas.1404386111. Epub 2014 Oct 6.

33.

Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.

Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW.

PLoS One. 2014 May 9;9(5):e96389. doi: 10.1371/journal.pone.0096389. eCollection 2014.

34.

Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis.

Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG.

PLoS One. 2013 Sep 17;8(9):e75466. doi: 10.1371/journal.pone.0075466. eCollection 2013.

35.

Large mobile genetic elements carrying resistance genes that do not confer a fitness burden in healthcare-associated meticillin-resistant Staphylococcus aureus.

Knight GM, Budd EL, Lindsay JA.

Microbiology. 2013 Aug;159(Pt 8):1661-72. doi: 10.1099/mic.0.068551-0. Epub 2013 May 31.

PMID:
23728624
36.

Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose.

Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, Tregoning JS, Baines DL.

Thorax. 2013 Sep;68(9):835-45. doi: 10.1136/thoraxjnl-2012-203178. Epub 2013 May 24.

37.

Shuffling of mobile genetic elements (MGEs) in successful healthcare-associated MRSA (HA-MRSA).

Lindsay JA, Knight GM, Budd EL, McCarthy AJ.

Mob Genet Elements. 2012 Sep 1;2(5):239-243.

38.

Clinical evaluation of diamine silver fluoride/potassium iodide as a dentine desensitizing agent. A pilot study.

Craig GG, Knight GM, McIntyre JM.

Aust Dent J. 2012 Sep;57(3):308-11. doi: 10.1111/j.1834-7819.2012.01700.x. Epub 2012 May 23.

39.

Shift in dominant hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) clones over time.

Knight GM, Budd EL, Whitney L, Thornley A, Al-Ghusein H, Planche T, Lindsay JA.

J Antimicrob Chemother. 2012 Oct;67(10):2514-22. doi: 10.1093/jac/dks245. Epub 2012 Jul 3.

PMID:
22761331
40.

Leave decay in my cavity? You must be kidding!

Knight GM, McIntyre JM, Craig GG, Mulyani.

Dent Today. 2010 Feb;29(2):130, 132-3. No abstract available.

PMID:
20196344
41.

Inability to form a biofilm of Streptococcus mutans on silver fluoride- and potassium iodide-treated demineralized dentin.

Knight GM, McIntyre JM, Craig GG, Mulyani, Zilm PS, Gully NJ.

Quintessence Int. 2009 Feb;40(2):155-61.

PMID:
19365897
42.

The inability of Streptococcus mutans and Lactobacillus acidophilus to form a biofilm in vitro on dentine pretreated with ozone.

Knight GM, McIntyre JM, Craig GG, Mulyani, Zilm PS.

Aust Dent J. 2008 Dec;53(4):349-53. doi: 10.1111/j.1834-7819.2008.00077.x.

43.

An in vitro investigation of marginal dentine caries abutting composite resin and glass ionomer cement restorations.

Knight GM, McIntyre JM, Craig GG, Mulyani, Zilm PS, Gully NJ.

Aust Dent J. 2007 Sep;52(3):187-92.

44.
45.
46.
47.
48.
49.
50.

Placement and replacement of restorations by selected practitioners.

Knight GM, Craig GG.

Aust Dent J. 2005 Sep;50(3):215; author reply 215. No abstract available.

Supplemental Content

Loading ...
Support Center